Till startsida
To content Read more about how we use cookies on gu.se

Contact form


Note! If you want an answer on a question you must specify your email address

Jan Lycke

Professor, adjungerad

Jan Lycke
Professor, adjungerad
+46 31-342 9047

Postal Address: Gröna stråket 11, plan 3, 41345 Göteborg
Visiting Address: Neurosjukvården, Gröna stråket 11, plan 3, SU/Sahlgrenska sjukhuset , 41345 Göteborg

Department of Clinical Neuroscience at Institute of Neuroscience and Physiology (More Information)
Box 430
405 30 Göteborg
Visiting Address: Blå stråket 7, plan 3, Sahlgrenska , 413 45 Göteborg

Latest publications

Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies
B. Van Wijmeersch, B. A. Singer, A. Boster, S. Broadley, O. Fernandez et al.
Multiple Sclerosis Journal, Journal article 2019
Journal article

Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis
M. Boremalm, A. Juto, Markus Axelsson, Lenka Novakova, T. Frisell et al.
European Journal of Neurology, Journal article 2019
Journal article

Cerebrospinal fluid NCAM levels are modulated by disease-modifying therapies
Markus Axelsson, N. Dubuisson, Lenka Novakova, Clas Malmeström, G. Giovannoni et al.
Acta Neurologica Scandinavica, Journal article 2019
Journal article

Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod
Fredrik Piehl, Ingrid Kockum, Mohsen Khademi, Kaj Blennow, Jan Lycke et al.
Multiple Sclerosis Journal, Journal article 2018
Journal article

Showing 51 - 60 of 69


Allmän neurologi och multipel skleros
Jan Lycke, Mats Elm
Neurologi. Läkemedelsboken 2011–2012 , Läkemedelsverket, Chapter in book 2011
Chapter in book

High nationwide prevalence of multiple sclerosis in Sweden.
Cecilia Ahlgren, Anders Odén, Jan Lycke
Multiple sclerosis (Houndmills, Basingstoke, England), Journal article 2011
Journal article

Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial.
Per Soelberg Sorensen, Jan Lycke, Juha-Pekka Erälinna, Astrid Edland, Xingchen Wu et al.
Lancet neurology, Journal article 2011
Journal article

A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis.
Carolina Holmén, Fredrik Piehl, Jan Hillert, Anna Fogdell-Hahn, Malin Lundkvist et al.
Multiple sclerosis (Houndmills, Basingstoke, England), Journal article 2011
Journal article

Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab.
Martin Gunnarsson, Clas Malmeström, Markus Axelsson, Peter Sundström, Charlotte Dahle et al.
Annals of neurology, Journal article 2011
Journal article


Leukocyte myeloperoxidase and pathogenesis of the post-polio syndrome
Charlotta Movitz, Tomas Bergström, Kristian Borg, Kristoffer Hellstrand, Erik Lycke et al.
Journal article

Showing 51 - 60 of 69

Page Manager: Katinka Almrén|Last update: 9/1/2015

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?

Denna text är utskriven från följande webbsida:
Utskriftsdatum: 2019-12-07